News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SIMCERE PHARMA (02096.HK) Self-Developed Antibody-Drug Conjugate SIM0613 Approved for Clinical Trial in China
SIMCERE PHARMA (02096.HK) announced that its self-developed LRRC15-targeting antibody-drug conjugate, SIM0613 for injection, has received a Clinical Trial Approval Notice issued by...
Reset
Send
The window will close in 5 seconds
SIMCERE PHARMA (02096.HK) Self-Developed Antibody-Drug Conjugate SIM0613 Approved for Clinical Trial in China
Close
Recommend
4
Positive
2
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

SIMCERE PHARMA (02096.HK)  -0.230 (-1.981%)    Short selling $23.37M; Ratio 22.818%   announced that its self-developed LRRC15-targeting antibody-drug conjugate, SIM0613 for injection, has received a Clinical Trial Approval Notice issued by the National Medical Products Administration of China. The drug is planned to commence clinical trials for advanced solid tumors. (ec/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.